

1 **Quality of life and associated factors among HIV positive patients after completion of**  
2 **treatment for Cryptococcal meningitis**

3 Authors: Jonathan Kitonsa<sup>1\*</sup>, Julius Kiwanuka<sup>2</sup>, Zacchaeus Anywaine<sup>1</sup>, Sheila Kansiime<sup>1</sup>,  
4 Kenneth Katumba<sup>1</sup>, Namirembe Aeron<sup>1</sup>, Justin Beardsley<sup>3,4</sup>, Freddie Kibengo<sup>1</sup>, Alastair  
5 Gray<sup>5</sup>, Pontiano Kaleebu<sup>1</sup>, Jeremy Day<sup>3,6</sup>

6 **Institutions**

7 **1** Medical Research Council / Uganda Virus Research institute & London School of Hygiene  
8 and Tropical Medicine Uganda Research Unit

9 **2** Department of Epidemiology and Biostatistics, School of Public Health, Makerere  
10 University Kampala, Uganda

11 **3.** Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme  
12 Vietnam, Ho Chi Minh City, Vietnam

13 **4.** Marie Bashir Institute, Westmead Clinical School, University of Sydney, Australia

14 **5.** Health Economics Research Centre, Nuffield Department of Population Health, University  
15 of Oxford, Oxford, UK

16 **6.** Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus,  
17 Headington, Oxford OX3 7BN UK

18

19

20 **\* Corresponding author**

21 Email: [Jonathan.Kitonsa@mrcuganda.org](mailto:Jonathan.Kitonsa@mrcuganda.org), [jonathankitonsa@yahoo.com](mailto:jonathankitonsa@yahoo.com) (JK)

22

23

24

## 25 **Abstract**

26 **Background:** Cryptococcal meningitis (CCM) remains one of the leading causes of  
27 mortality among HIV infected patients. Due to factors such as the severity of CCM  
28 pathology, the quality of life (QOL) of patients post-treatment is likely to be poor. Few  
29 studies have reported on QOL of CCM patients post treatment completion. We used data  
30 collected among patients in the CryptoDex trial (ISRCTN59144167) to determine QOL and  
31 associated factors at week 10 and six months from treatment initiation.

32 **Methodology:** CryptoDex was a double-blind placebo-controlled trial of adjunctive  
33 dexamethasone in HIV infected adults with CCM, conducted between 2013 and 2015 in six  
34 countries in Asia and Africa. QOL was determined using the descriptive and Visual Analog  
35 Scales (VAS) of the EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We derived  
36 index scores, and described these and the VAS scores at 10 weeks and 6 months; and used  
37 linear regression to determine the relationship between various characteristics and VAS  
38 scores at both time points.

39 **Results:** Of 451 patients enrolled in the trial, 238 had QOL evaluations at week 10. At  
40 baseline, their mean age (SD) was 35.2(8.5) years. The overall mean VAS score (SD) at 10  
41 weeks was 57.2 (29.7), increasing significantly to 72(27.4) at month six ( $p<0.001$ ). The  
42 overall mean VAS score (SD) at week 10 was 57.2(29.7), increasing significantly to 72(27.4)  
43 at month six, ( $p<0.001$ ). At week 10, higher VAS score was associated with absence of confusion  
44 ( $p=0.039$ ), greater weight ( $p=0.002$ ), and being African ( $p<0.001$ ). At month six, higher VAS score  
45 remained associated with African origin ( $p=0.019$ ). Higher number of inpatient days was  
46 associated with worse VAS scores at 10 weeks and 6 months ( $p<0.001$  and  $p=0.006$   
47 respectively).

48 **Conclusion:** QOL was good among patients that had completed therapy for CCM, but  
49 below perfect. Strategies to improve QOL among CCM survivors are required.

50 **Key words:** Quality of life, Cryptococcal meningitis, HIV, Treatment completion

51

## 52 **Lay summary**

53 In spite of the remarkable reduction in the incidence of Cryptococcal meningitis (CCM), with  
54 increased use of antiretroviral therapy, incidence remains unacceptably high especially in  
55 sub-Saharan Africa and Asia where more than 90% of the cases and deaths occur.

56 Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients  
57 post-treatment is also likely to be poor. Few studies have reported on QOL of CCM patients  
58 post treatment completion. We used data collected among patients in the CryptoDex trial  
59 (ISRCTN59144167) to determine self-perceived QOL and associated factors among 238  
60 survivors at week 10 and 203 survivors at six months from treatment initiation.

61 We determined QOL using the descriptive and Visual Analog Scales (VAS) of the EuroQol  
62 Five-Dimension-Three-Level (EQ-5D-3L) tool.

63 We found that while self-perceived QOL was only relatively good among this cohort of  
64 patients who had survived through treatment for CCM, it continued to improve over the 6  
65 months following diagnosis. Low weight at diagnosis, prolonged hospital admission, and  
66 being Asian were associated with lower QOL. QOL is an important outcome that should be  
67 considered among HIV infected patients treated for serious infections such as CCM.

68

69

70

71

72

73

## 74 **Introduction**

75 Cryptococcal meningitis (CCM) is one of the leading causes of mortality among HIV  
76 infected patients, especially in sub-Saharan Africa and Asia. Mortality from CCM remains  
77 high, in spite of a significant reduction in the incidence of opportunistic infections (OIs),  
78 resulting from improvement in HIV management including early initiation of antiretroviral  
79 therapy (ART) [1]. Between 2009 and 2014, the estimated global annual prevalence and  
80 mortality due to CCM reduced from 975,900 to 223,100 and 624,700 to 181,100 respectively  
81 [2,3]. While incidence, prevalence, and mortality indices have been used widely to  
82 demonstrate the burden of CCM amongst HIV infected patients, its effects on other important  
83 measures of health such as quality of life (QOL) have not been adequately evaluated. Due to  
84 the advanced stage of AIDS at which CCM occurs, severity of disease pathology, toxicity of  
85 antifungal medications and disease sequelae, the QOL post-treatment is likely to be poor. We  
86 previously showed that patients with low QOL at treatment completion are more likely to die  
87 two years later than those with higher QOL[4]. Previous research has demonstrated that QOL  
88 measurements amongst HIV infected patients should be done routinely [5-8], since improved  
89 QOL is one of the ultimate goals of HIV management. We used data collected from patients  
90 enrolled in the CryptoDex trial (PMID: 25391338, ISRCTN59144167) [9,10] to determine  
91 QOL at 10 weeks and six months since treatment initiation and the factors associated with  
92 QOL at 10 weeks and six months.

93

94

95

96

97

98

## 99 **Methodology**

### 100 **Study design and setting**

101 The CryptoDex trial was a double-blind placebo-controlled phase III trial of adjunctive  
102 dexamethasone in HIV infected adults with cryptococcal meningitis. The study was  
103 conducted between 2013 and 2015 at thirteen sites in six countries in Asia and Africa  
104 (Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi).

### 105 **Subjects enrolled in the CryptoDex study and their management**

106 Patients recruited in the CryptoDex study were 18 years and above, had HIV infection, a  
107 clinical syndrome consistent with CCM, and microbiological confirmation of disease, as  
108 indicated by one or more of the following test results: 1) positive India ink staining of  
109 cerebral spinal fluid (CSF); 2) culture of *Cryptococcus* species from CSF or blood; or 3)  
110 cryptococcal antigen detected in CSF on cryptococcal antigen lateral flow assay (IMMY).  
111 Exclusion criteria included pregnancy, renal failure, gastrointestinal bleeding, having been  
112 treated with more than 7 days of anticytotoxic antifungal therapy, and being on or  
113 requiring glucocorticoid therapy for coexisting conditions. Informed consent was obtained  
114 from all patients or a next of kin where a patient was not in position to consent. Eligible  
115 patients were randomised in a 1:1 ratio, stratified by site, to receive either dexamethasone  
116 adjunctive therapy or placebo in a tapered dose until 42 days post-randomisation. Details of  
117 other study procedures and investigations can be found in the CryptoDex study protocol [11].  
118 The treatment regimen included an induction phase with intravenous Amphotericin B (1  
119 mg/kg/day) and oral Fluconazole 800mg daily for 14 days, followed by a continuation phase

120 of 800mg daily fluconazole for eight weeks, and then a maintenance phase with oral  
121 fluconazole 200mg daily. This regimen was consistent with the WHO treatment  
122 recommendation for settings where Flucytosine was not available at the time the trial was  
123 conducted [12].

124 Patients were followed up in the study until six months after enrolment, at which point they  
125 were exited and referred back to their HIV care clinics for continuation of HIV care.

## 126 **Subjects included in this analysis**

127 This QOL analysis includes patients who survived up to 10 weeks post-treatment initiation  
128 when the first QOL assessment was performed. A second QOL assessment was done at  
129 month six and therefore patients who had not died between 10 weeks and six months and  
130 were accessible i.e., able to come to the clinics, are included in the six months analysis.

## 131 **Variables and their measurement in the CryptoDex study**

132 Quality of life was measured using the EQ-5D-3L tool [13]. This tool gives a subjective  
133 measure for the QOL, which is in line with the definition of QOL by WHO. The WHO  
134 defines QOL as an individuals' perception of their position in the context of culture and value  
135 systems in which they live and in relation to their goals, expectations, standards, and  
136 concerns [14]. The tool is a widely used measure of health status consisting of two parts. The  
137 first part (the descriptive system) assesses health in five dimensions (mobility, self-care, usual  
138 activities, pain/discomfort, and anxiety/depression). Each dimension has three levels of  
139 response (no problems, some problems, extreme problems/not able to). This part of the EQ-  
140 5D-3L questionnaire provides a descriptive profile that can be used to generate a health state  
141 profile. For example, a patient in health state 11233 would have no problems in mobility and  
142 self-care, some problems with usual activities, severe/extreme pain/discomfort, and extreme  
143 anxiety or depression. Each health state is assigned a summary index score based on societal

144 preference weights for the health state. Health state index scores generally range from less  
145 than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than  
146 death) to 1 (perfect health). Health state preferences can differ between countries. Where a  
147 value set is not available for a country/region, the assessor can opt to select a value set for a  
148 country/region considered to most closely approximate the country of interest [13]. We used  
149 the Thailand value set for sites in Asia (Vietnam, Thailand, Indonesia and Laos) [15] and the  
150 Zimbabwe value set for sites in Africa (Uganda and Malawi) [16]. The second part of the  
151 EQ-5D-3L questionnaire consists of a visual analog scale (VAS) on which the patient rates  
152 his/her self-perceived health from 0 (the worst imaginable health) to 100 (the best imaginable  
153 health/perfect health).

154 The tool was translated into the local languages and administered by a study doctor who read  
155 the questions to the patient. Other details concerning its administration can be found in the  
156 study protocol [11].

157 We measured the impact of a number of variables on QOL measured using the VAS score  
158 including: demographic characteristics (age, sex, and education measured as number of years  
159 in school); continent, i.e. Asia or Africa; ART status, i.e. on or not on ART; time on ART;  
160 most recent CD4 count at enrolment; presence of convulsions; intervention arm, i.e.,  
161 dexamethasone or placebo; Number of inpatient days by week 10 and month six, baseline  
162 CSF fungal burden, and Number of adverse events (neurological events, new AIDs defining  
163 illnesses, other adverse events, and immune reconstitution syndrome events).

164

165

166

167

168

## 169 **Data Analysis**

170 All data from the CryptoDex study was derived from the secure OUCRU proprietary CLiRES  
171 trial database. Data were extracted into a Microsoft Access database for export to STATA  
172 (College Station, TX, version 15.0). Categorical variables were summarised by frequencies  
173 and percentages, while continuous variables were summarised using means (standard  
174 deviations) and/or medians (interquartile ranges).

175 A health profile was generated by continent and time points (i.e., week 10 and month six),  
176 from which we derived a health state index score using the selected value sets for each  
177 region. We then summarised the index scores by means, standard deviations (SD), and  
178 minimum and maximum scores by continent at the different time points. VAS scores were  
179 interpreted as very good (81-100), good (51-80), normal (31-50) and bad/very bad (0-30)  
180 [17]. T-tests were used to compare VAS scores between continents and to test for significant  
181 changes in VAS scores and index scores at the different time points. We also computed and  
182 presented percentages of categories under each of the five dimensions of the EQ-5D-3L  
183 questionnaire.

184 We used simple linear regression to determine crude associations between VAS scores at  
185 week 10 and month six and various variables. This analysis was not repeated using index  
186 scores as two value sets (Thailand and Zimbabwe) were used, and sample sizes were too  
187 small to conduct separate analyses. Variables that had a p-value of 0.2 and below at  
188 univariate analysis were included in a multivariable linear regression model. Variables were  
189 retained in the multivariable model if their inclusion did not make the model significantly  
190 worse at LRT p-value 0.05.



## 191 **Ethical considerations**

192 The CryptoDex study received ethical approval from each country's respective regulatory  
193 authorities, and the Oxford Tropical Ethics Committee as indicated in the published protocol  
194 and study paper [9,10].

## 195 **Results**

196 \* Patients were not able to come to clinics to have QOL assessment.

197 **Fig 1: Flow diagram showing participants enrolled in CryptoDex trial who had quality**  
198 **of life evaluations done.**

199

## 200 **Baseline Characteristics:**

201 Figure 1 is a flow diagram showing the patients included in this analysis. Out of 823 patients  
202 screened at the 13 sites globally, 451 were found eligible and randomized. One patient was  
203 subsequently excluded because he never received the assigned study drug due to an  
204 administrative error. Out of the remaining 450 patients, 251 (55.8%) survived to week 10  
205 post-treatment initiation, and 238 (94.8%) completed a QOL assessment and were included in  
206 our analysis. The other 13 (5.2%) patients were not accessible for the quality of life  
207 assessment since they did not come to the clinics. At baseline, the mean age (SD) of the 238  
208 patients was 35.2 (8.5) years, and 101 (42.4%) were on ART. The median CD4 count (IQR)  
209 was 30 (13, 71) cells/ml. Thirty (12.6%) patients reported a history of convulsions. Of the  
210 238 patients, 113 (47.5%) had been randomised to receive dexamethasone adjunctive therapy.  
211 The baseline characteristics are summarised in Table 1.

212 **Adverse events:**

213 Four hundred and thirty four adverse events were captured among these participants,  
 214 including 67 new neurological events, 93 new AIDs defining illnesses, 365 other adverse  
 215 events, and 9 immune reconstitution syndrome events.

216

217

218

219

220 **Table 1: Baseline characteristics of the patients that had QOL evaluation at 10 weeks**

		Africa	Asia	Overall
Variable	Level	Frequency (%)	Frequency (%)	Frequency (%)
Gender (n=238)	Male	71(57.3)	81(71.1)	152(63.9)
	Female	53(42.7)	33(29.0)	86(36.1)
Mean age (SD), (n=238)		34.9(8.7)	35.7(8.3)	35.2(8.5)
Median CD4 (IQR), (n=126)*		40(15, 104)	25(9, 51)	30(13, 71)
Years in school (n=215)**	≤7	63(57.3)	44(41.9)	107(49.8)
	>7	47(42.7)	61(58.1)	108(50.2)
Glasgow coma Score (n=238)	15+	107(86.3)	103(90.4)	210(88.2)
	<15	17(13.7)	11(9.6)	28(11.8)
Period known to have HIV in years (179)		0.5(0.2, 2)	0.2(0.1, 1.9)	0.4(0.1, 1.9)
On ARVs (n=238)	No	53(42.7)	84(73.7)	137(57.6)
	Yes	71(57.3)	30(26.3)	101(42.4)
Confusion (n=238)	No	83(66.9)	97(85.1)	180(75.6)
	Yes	41(33.1)	17(14.9)	58(24.4)
Mean Weight (SD) (n=238)		52.7(10.8)	51.5(9.3)	52.1(10.1)
Convulsion (n=238)	No	117(94.3)	91(79.8)	208(87.4)
	Yes	7(5.7)	23(20.2)	30(12.6)
Intervention (n=238)	Dexamethasone	55(44.4)	58(50.9)	113(47.5)
	Placebo	69(55.6)	56(49.1)	125(52.5)
CSF Culture, CFU/ml (n=227)***	<1000cfu/ml	47(39.8)	31(28.4)	78(34.4)
	≥1000cfu/ml	71(60.2)	78(71.6)	149(65.6)

221 **Abbreviations:** n, Number; ARVs, Anti retro viral therapy; SD, Standard deviation; HIV, Human

222 immunodeficiency virus; %, percentage; CFU/ml, Colony forming units per millilitre.

223 \*Pre-enrolment CD4s considered. CD4s were not repeated in the study. Some patients had no record of CD4  
 224 counts.

225 \*\*Responses could not be got for some participants because of altered consciousness.

226 \*\*\*Lumbar punctures were not successful in a few patients.

227

## 228 **Quality of life assessment**

229 **Descriptive system and index scores:** Health profile results for patients at both time points  
 230 are summarised in Table 2. There was no difference in the proportion of patients from Africa  
 231 or Asia rating themselves as having perfect health (i.e., profile 11111) at 10 weeks (Africa:  
 232 40 of 124 (32.3%); Asia: 37 of 114 (32.5%)). At this time point, 4 Asian patients (3.5%) rated  
 233 themselves as having the worst health state possible i.e. 33333 compared with 1 African  
 234 patient (0.8%, p=0.2). At month six, reported quality of life had increased in both African and  
 235 Asian centres, with 58 of 104 (55.8%) Africans and 48 of 99 (48.5%) Asians rating  
 236 themselves as having perfect health (p=0.2).

237 At week 10, the mean index scores (SD, range) were 0.785 (0.2, -0.145 to 1) and 0.619 (0.4, -  
 238 0.452 to 1) for African and Asian patients respectively, increasing significantly at month six,  
 239 to 0.879 (0.2, 0.341 to 1), p=0.002 and 0.731 (0.4, -0.452 to 1), p=0.052 for African and  
 240 Asian patients respectively.

241

242 **Table 2: Health profile scores for patients at week 10 and month six**

CONTINENT	Level	Mobility		Self-care		Usual activities		Pain/discomfort		Anxiety/ depression	
		Week	Month	Week 10	Month	Week	Month	Week	Month	Week	Month
		10	six	n (%)	six	10	six	10	six	10	six
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
<b>AFRICA</b>	<b>1(no</b>	<b>79(63.7)</b>	<b>84(80.8)</b>	<b>102(82.3)</b>	<b>99(95.2)</b>	<b>59(51.8)</b>	<b>72(69.2)</b>	<b>72(58.1)</b>	<b>75(72.1)</b>	<b>78(63.4)</b>	<b>79 (76)</b>

	problems)										
	2(some problems)	39(31.5)	20(19.2)	14(11.3)	4(3.8)	35(30.7)	25(24.1)	47(37.9)	28(26.9)	37(30.1)	21(21.1)
	3(extreme problems)	6(4.8)	0	8(6.4)	1(1)	20(17.5)	7(6.7)	5(4)	1(1)	8(6.5)	3(2.9)
ASIA	1(no problems)	71(62.3)	72(72.7)	83(72.8)	85(85.9)	59(51.8)	68(68.7)	60(53.1)	61(61.6)	76(68.5)	69(70.4)
	2(some problems)	28(24.5)	22(22.2)	16(14)	8(8.1)	35(30.7)	20(20.2)	42(37.2)	33(33.3)	28(25.2)	22(22.5)
	3(extreme problems)	15(13.2)	5(5.1)	1 (13.2)	6(6)	20(17.5)	11(11.1)	11(9.7)	5(5.1)	7(6.3)	7(7.1)

243 **Abbreviations:** n, Number; %, percentage.

## 244 **EQ VAS scale results**

245 The overall mean VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72  
 246 (27.4) at month six ( $p < 0.001$ ), both mean scores falling within category 51-80, i.e. “Good  
 247 QOL”. The mean score (SD) at 10 weeks was significantly higher among African patients  
 248 than Asian patients i.e., 65.7 (21.5) vs 47.5 (34.5),  $p < 0.001$ . Similarly the mean score (SD) at  
 249 six months was significantly higher among African patients compared to Asian patients i.e.,  
 250 79 (17.7) vs 64.2 (33.4),  $p < 0.001$ .

251 Mean VAS and Index scores at week 10 and month six are represented in Figure 2.

252

253 Abbreviations: VAS, Visual analog scale; QoL, Quality of life.

254 **Fig 2: Mean VAS scores and Index scores at week 10 and 6 months after treatment**  
 255 **initiation**

256

## 257 **Factors associated with quality of life**

258 Results from the univariate and multivariate analysis are summarised in Table 3.

259 At week 10, the baseline factors associated with higher VAS score at multivariate analysis  
 260 were: greater weight (regression coefficient 0.6, 95% CI: 0.2 to 1), p=0.002; and being from  
 261 Africa (regression coefficient 15.6, 95% CI: 7.3 to 24.1), p<0.001. Higher inpatient days by  
 262 week 10 was associated with poorer VAS score (regression coefficient -0.8, 95% CI -1.1 to -  
 263 0.4), p<0.001.

264 At month six, the only factor associated with higher VAS score at multivariate analysis was  
 265 African origin (regression coefficient 12.8 95% CI 2.6 to 23.1), p=0.015. Again, higher  
 266 inpatient days was associated with a reduced VAS score at 6 months (regression coefficient -  
 267 0.6, 95% CI -1.0 to -0.3, p=<0.001).

268

269

270 **Table 3: Quality of Life and associated factors at 10 weeks and 6 months**

		WEEK 10				WEEK SIX			
Variable	Categories	Univariate linear regression		Multivariate linear regression		Univariate linear regression		Multivariate linear regression	
		Reg. Coef. (95% CI)	P Value	Reg. Coef. (95% CI)	P Value*	Reg. Coef. (95% CI)	P Value	Reg. Coef. (95% CI)	P Value*
Gender	Male								
	Female	6(-2.1 to 14.1)	0.145	6.3(-1.7 to 14.4)	0.122	2.8(-5.2 to 10.8)	0.497		
Age	Cont.	-0.1(-0.5 to 0.4)	0.852			-0.4(-0.9 to 0.2)	0.173	-0.2(-0.7 to 0.3)	0.432
Years in School	≤7								
	>7	-0.7(-9 to 7.6)	0.862			-2.2(-10.4 to 5.9)	0.588		
Glasgow coma Score	<15								
	15	7.2(-4.6 to 19.0)	0.230	1.9(-10.4 to 14.2)	0.759	3.7(-8.3 to 15.7)	0.547		
ART at Baseline	Yes								
	No	-6.2(-14.0 to 1.6)	0.121	3.0(-4.9 to 10.8)	0.455	-7.7(-15.4 to 0.03)	0.051	4.1(-5.1 to 13.3)	0.383
Confusion	Yes								
	No	7.2(-1.7 to 16.1)	0.114	7.5(-2.1 to 17.2)	0.126	-1.2(-10.1 to 7.6)	0.789		
Weight	Cont.	0.5(0.2 to 0.9)	0.005	0.6(0.2 to 1.0)	0.002	0.2(-0.2 to 0.5)	0.397		
Convulsion	Yes								

	<b>No</b>	11.9(0.3 to 23.4)	0.044	-0.8(-12.2 to 10.5)	0.885	5.5(-6.4 to 17.2)	0.366		
<b>Inpatient days by week 10</b>	<i>Cont.</i>	-0.7(-1.1 to -0.4)	<0.001	-0.8(-1.1 to -0.4)	<0.001	N/A	N/A		
<b>Inpatient days by month six</b>	<i>Cont.</i>	N/A	N/A	N/A	N/A	-0.5(-0.7 to -0.2)	<0.001	-0.6(-1.0 to -0.3)	<0.001
<b>Intervention</b>	<b>Dexa.</b>								
<b>Continent</b>	<b>Placebo</b>	4.9(-2.9 to 12.6)	0.220	1.4(-6.0 to 8.9)	0.699	5.1(-2.6 to 12.8)	0.193	3.8(-5.0 to 12.6)	0.391
	<b>Asia</b>								
	<b>Africa</b>	18.2(10.8 to 25.6)	<0.001	15.6(7.3 to 24.1)	<0.001	14.8(7.4 to 22.2)	<0.001	12.8(2.6 to 23.1)	0.015
<b>CSF Culture, CFU/ml</b>	<b>&lt;1000</b>								
	<b>≥1000</b>	-6.5(-14.7 to 1.6)	0.116	0.9(-7.1 to 8.9)	0.821	-4.9(-12.9 to 3.1)	0.231	-0.9(-9.7 to 7.9)	0.835
<b>Adverse events</b>	<b>None</b>								
	<b>1-3</b>	-1.0(-10.5 to 8.5)	0.841	5.2(-4.2 to 14.5)	0.277	-3.1(-12.3 to 6.0)	0.498	9.1(-1.6 to 19.8)	0.093
	<b>4+</b>	-10.2(-22.0 to 1.6)	0.09	9(-4.1 to 22.1)	0.177	-10(-22.2 to 2.2)	0.107	15.1(-2.6 to 32.8)	0.094

271 **Abbreviations:** ART, Antiretroviral therapy; CI, Confidence interval; Reg, Regression; Coef, Coefficient;

272 Cont. Continuous variable; N/A, Not applicable; Dexa, Dexamethasone; CFU/ml, Colony forming units per  
273 millilitre.

274 \* Only variables with a P Value <0.2 in the univariate analysis were used in the multivariable linear regression  
275 model.

276

277

278

279

280

281

282

283

284

285

286

287

288

289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302

## 303 **Discussion**

304 HIV-associated CCM is an extremely debilitating disease associated with high mortality.  
305 Affected patients present with advanced HIV disease and considerable immunosuppression.  
306 While the disease itself is associated with significant risks of sequelae including neurological  
307 deficits, the treatment itself, of which amphotericin is the backbone, is also associated with  
308 significant toxicities [18,19]. All these factors have the potential to reduce the QOL among  
309 patients who survive up to treatment completion.

310 We were pleased to see that many patients reported relatively good self-perceived QOL  
311 following completion of treatment for CCM, and that this tended to improve thereafter  
312 through the 6 months following diagnosis. However, given the nature of the disease and its  
313 treatment, it is perhaps not surprising that very few patients reported ‘very good’ or ‘perfect’  
314 health. We did not assess the QOL at study entry in the CryptoDex trial and thus could not  
315 measure improvement directly attributable to antifungal treatment. However, we found that

316 patients reported significant improvements in QOL between 10 weeks and six months after  
317 diagnosis, both with the descriptive and VAS scales. These continuing improvements in QOL  
318 are likely due to multiple factors. These may include gradual improvement due to  
319 neurological recovery, better engagement with health services, and the use of antiretroviral  
320 drugs. A previous study identified that patients with CCM had significant improvements in  
321 QOL compared with pre-treatment scores [5]. It has been shown previously that different  
322 antifungal combinations can be associated with long term (6 month) differences in  
323 survival[9]. Therefore, while some of the improvement in QOL seen in our patients, who all  
324 received the same antifungal treatment, may be due to the factors we described above,  
325 developing more effective induction and consolidation therapy for CCM is likely to yield  
326 further improvements in QOL.

327

328 We consider QOL an important health parameter to measure since better scores have been  
329 shown to correlate with long term survival [4,20]. In our study, we used the EQ-5D-3L tool.  
330 This has the advantages of simplicity and ease of administration including amongst very sick  
331 patients, as well as ease of scoring and interpretation. While it has not been used previously  
332 in many studies of CCM patients, our work shows that it can identify changes in QOL over  
333 time following treatment of CCM. As such, it has the potential to identify patients who may  
334 benefit from increased follow-up during the recovery process – further studies are needed.  
335 Identifying such patients could help with distribution of scarce resources and ensure the best  
336 possible outcomes for all patients.

337

338 We found that prolonged admission by week 10 and month 6 were associated with lower  
339 QOL measured using the VAS at week 10 and month six. This is not surprising - patients



340 admitted for longer periods were likely more ill at baseline. A similar finding was reported in  
341 a study done by Naftoux and colleagues in Belgium [21].

342 We were surprised to see that patients from African countries in the CryptoDex trial rated  
343 themselves to have better QOL at week 10 and six months than did Asian patients. This effect  
344 was seen with both the descriptive scale and VAS. This effect remained apparent even after  
345 adjustment for other factors that affected QOL. We suggest that this is probably a societal  
346 perceptual variation rather than an indication of impact of disease, although its inverse  
347 correlation with the gross national income per capita for the Asian and African countries was  
348 counter-intuitive. We also found that higher weight was associated with higher VAS at week  
349 10. The most likely explanation here is that low weight is correlated with more severe disease  
350 [22]. Unlike a previous study from Uganda amongst HIV patients that found male gender was  
351 associated with better quality of life, we did not identify a difference between males and  
352 females in terms of QOL following treatment for CCM [23].

353 Our analysis has some limitations. First, we used a subjective measure of QOL, which may  
354 not be an absolute indication of the QOL of an individual. Naturally, optimistic people may  
355 rate their health status higher than pessimistic ones. However, the WHO recommends that  
356 QOL tools should measure from the subjective viewpoint since the patients experience is  
357 more relevant than the assessment of an objective observer [24]. Second, we used health  
358 index scores derived from models of countries that we assumed were similar to our own,  
359 since models do not exist for all the countries in our study. Use of validated index scores  
360 from the actual countries that participated in CryptoDex could conceivably result in different  
361 outcomes. However, we think this is unlikely because we measured QOL at two time points  
362 and found improvement over time.

363 Going forward, we would recommend that QOL assessment should be part of all trials in  
364 cryptococcal meningitis. Recent work from Molloy and colleagues has suggested that current

365 doses of amphotericin, which clearly have the greatest antifungal effect, may in fact be  
366 resulting in patient harm because of associated toxicities [25]. QOL measurements among  
367 survivors could help in parsing such data, while we wait for more effective and tolerable  
368 novel treatments to be developed.

## 369 **Conclusion**

370 While self-perceived QOL was only relatively good among this cohort of patients who had  
371 survived through treatment for CCM, it continued to improve over the 6 months following  
372 diagnosis. Low weight at diagnosis, prolonged hospital admission, and being Asian were  
373 associated with lower perceived QOL. QOL is an important outcome that should be  
374 considered among HIV infected patients treated for serious infections such as CCM.

375

## 376 **Acknowledgements**

377 We would like to appreciate the team that implemented the CryptoDex trial at all the sites in  
378 Africa and Asia.

379 We are especially grateful to the study participants and/or their representatives for the  
380 precious time they accorded us.

381 The content is solely the responsibility of the authors and does not necessarily represent the  
382 official views of the supporting agencies.

383

## 384 **Author Contributions**

385 Conceived and designed the experiments: Jonathan Kitonsa. Performed the  
386 experiments: Jonathan Kitonsa, Freddie Kibengo and Zacchaeus Anywaine. Analysed the  
387 data: Julius Kiwanuka, Sheila Katusiime, and Jonathan Kitonsa. Wrote the paper: Jonathan

388 Kitonsa, Julius Kiwanuka, Freddie Kibengo, Kenneth Katumba, Zacchaeus Anywaine,  
389 Pontiano Kaleebu, Alastair Gray, and Jeremy Day.

390

391

392

393

394

395

396

397 **References**

398

- 399 1. Grinsztejn B, Hosseinipour MC, Ribaud HJ, Swindells S, Eron J, et al. (2014) Effects of  
400 early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-  
401 1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The  
402 Lancet Infectious diseases 14: 281-290.
- 403 2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009)  
404 Estimation of the current global burden of cryptococcal meningitis among persons  
405 living with HIV/AIDS. AIDS 23: 525-530.
- 406 3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, et al. (2017) Global burden  
407 of disease of HIV-associated cryptococcal meningitis: an updated analysis. The  
408 Lancet Infectious Diseases 17: 873-881.
- 409 4. Kitonsa J, Mayanja Y, Aling E, Kiwanuka J, Namutundu J, et al. (2019) Factors affecting  
410 mortality among HIV positive patients two years after completing recommended  
411 therapy for Cryptococcal meningitis in Uganda. PLoS One 14: e0210287.

- 412 5. Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW (2015) Factors That  
413 Affect Quality of Life among People Living with HIV Attending an Urban Clinic in  
414 Uganda: A Cohort Study. PLOS ONE 10: e0126810.
- 415 6. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, et al. (2011) Life Expectancy of Persons  
416 Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort  
417 Analysis From Uganda. Annals of Internal Medicine 155: 209-216.
- 418 7. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK (2002) Health-Related  
419 Quality-of-Life Assessments and Patient-Physician CommunicationA Randomized  
420 Controlled Trial. JAMA 288: 3027-3034.
- 421 8. Degroote S, Vogelaers D, Vandijck DM (2014) What determines health-related quality of  
422 life among people living with HIV: an updated review of the literature. Archives of  
423 Public Health 72: 40.
- 424 9. Day J, Imran D, Ganiem AR, Tjahjani N, Wahyuningsih R, et al. (2014) CryptoDex: a  
425 randomised, double-blind, placebo-controlled phase III trial of adjunctive  
426 dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol  
427 for a randomised control trial. Trials 15: 441.
- 428 10. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, et al. (2016) Adjunctive  
429 Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med 374: 542-  
430 554.
- 431 11. Day J, Imran D, Ganiem AR, Tjahjani N, Wahyuningsih R, et al. (2014) CryptoDex: a  
432 randomised, double-blind, placebo-controlled phase III trial of adjunctive  
433 dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol  
434 for a randomised control trial. Trials 15: 441.
- 435 12. Sloan DJ, Parris V (2014) Cryptococcal meningitis: epidemiology and therapeutic  
436 options. Clinical Epidemiology 6: 169-182.

- 437 13. EuroQol (2018) EuroQol Research Foundation. EQ-5D-3L User Guide
- 438 14. WHOQOL Measuring Quality of Life. 1997.
- 439 15. Sirinart Tongsiri JC (2011) Estimating Population-Based Values for EQ-5D Health States  
440 in Thailand. Elsevier.
- 441 16. Jennifer Jelsma KH, Willy de Weerd, Paul de Cock and Paul Kind (2003) How do  
442 Zimbabweans value health states? BioMed Central.
- 443 17. Ivanise Arouche Gomes de Souza CCdAP, Andrea Liborio Monteiro (2018) Assessment  
444 of quality of life using the EQ-5D-3L instrument for hospitalised patients with  
445 femoral fracture in Brazil. BMC 16.
- 446 18. Tenforde MW, Wake R, Leeme T, Jarvis JN (2016) HIV-Associated Cryptococcal  
447 Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings.  
448 Current clinical microbiology reports 3: 92-102.
- 449 19. Boyer-Chammard T, Temfack E, Alanio A, Jarvis J, Harrison T, et al. (2019) Recent  
450 advances in managing HIV-associated cryptococcal meningitis [version 1; peer  
451 review: 2 approved]. F1000Research 8.
- 452 20. Cunningham WE, Crystal S, Bozzette S, Hays RD (2005) The Association of Health-  
453 related Quality of Life with Survival Among Persons with HIV Infection in the  
454 United States. Journal of General Internal Medicine 20: 21-27.
- 455 21. Philippe Nafteux JD, Johnny Moons, Willy Coosemans, Georges Decker, Toni Lerut,  
456 Hans Van Veer, Paul De Leyn (2013) Assessing the relationships between health-  
457 related quality of life and postoperative length of hospital stay after oesophagectomy  
458 for cancer of the gastro-oesophageal junction. European Journal of Cardio-Thoracic  
459 Surgery 44.

- 460 22. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ (2001) A  
461 prospective study of AIDS-associated cryptococcal meningitis in Thailand treated  
462 with high-dose amphotericin B. *The Journal of infection* 43: 226.
- 463 23. Mutabazi-Mwesigire D KA, MartinnF, Seeley J, Wu AW (2015) Factors That Affect  
464 Quality of Life among People Living with HIV Attending an Urban Clinic in Uganda:  
465 A Cohort Study. *PLoS ONE*.
- 466 24. WHO. (2020) Health statistics and information systems: Measuring quality of life.
- 467 25. Sile F, Molloy CK, Robert S. Heyderman, Angela Loyse, Duncan Chanda, Sayoki  
468 Mfinanga, Elvis Temfack (2018) Antifungal Combinations for Treatment of  
469 Cryptococcal Meningitis in Africa. *N Engl J Med* 378: 1004-1017.
- 470



